Herz-Zentrum Bad Krozingen, Südring 15, Bad Krozingen, Germany
Cardiol Rev. 2012 May-Jun;20(3):111-7. doi: 10.1097/CRD.0b013e31824394e1.
In recent years, a wide range of novel biomarkers have been evaluated for different cardiovascular disease states (eg, ischemia, congestion, and physiological stress), and many have shown promising results for the prediction of cardiovascular end points. However, to become useful for clinicians and to allow for personalized medicine, each novel biomarker must fulfill 3 fundamental criteria: (1) it must be easy to measure; (2) it must provide new information; and (3) it must help the clinician to manage patients. Although many biomarkers may be useful for prognostication, very few have been shown to improve the treatment of patients with cardiovascular disease when implemented in a clinical setting.
近年来，人们评估了多种新型生物标志物，用于不同的心血管疾病状态（如缺血、淤血和生理应激），其中许多生物标志物在预测心血管终点方面显示出很有前景的结果。然而，为了对临床医生有用并实现个体化医疗，每种新型生物标志物都必须满足 3 个基本标准：（1）必须易于测量；（2）必须提供新信息；（3）必须帮助临床医生管理患者。尽管许多生物标志物可能对预后有用，但很少有研究表明，在临床环境中实施时，它们可以改善心血管疾病患者的治疗效果。
